Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Transgene adds Jennerex anticancer asset to sculpt three-pillar strategy

This article was originally published in Scrip

Executive Summary

In an attempt to boost its chances of becoming profitable by 2015, the French biopharmaceutical company Transgene has acquired from Jennerex BioTherapeutics exclusive rights in Europe, the Commonwealth of Independent States (CIS) and the Middle East to JX-594, a modified oncolytic virus that targets the E2F pathway, to treat hepatocellular carcinoma (HCC). E2F is a protein that has a key role in cell proliferation and death.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts